Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Piergiuseppe Agostoni, Centro Cardiologico Monzino
ClinicalTrials.gov Identifier:
NCT00361127
First received: August 4, 2006
Last updated: January 27, 2016
Last verified: January 2016

August 4, 2006
January 27, 2016
August 2006
December 2013   (final data collection date for primary outcome measure)
Possible identification of a genetic pattern responsible for different responses to ACE-inhibition during fluid overload in heart failure [ Time Frame: Third day ] [ Designated as safety issue: No ]
Possible identification of a genetic pattern responsible for different response to ACE-inhibition during fluid overload in heart failure.
Complete list of historical versions of study NCT00361127 on ClinicalTrials.gov Archive Site
  • Influence of ACE-genotype on exercise capacity [ Time Frame: Third day ] [ Designated as safety issue: No ]
  • Influence of ACE-genotype on lung function [ Time Frame: Third day ] [ Designated as safety issue: No ]
  • Influence of ACE-genotype on exercise capacity
  • Influence of ACE-genotype on lung function
Not Provided
Not Provided
 
Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure
Influence of ACE Genotype on Lung Diffusion at Rest and After Fluid Overload in Heart Failure Patients Treated With ACE-inhibitors
In patients with chronic heart failure ACE-inhibitor treatment improves lung diffusion and prevents pulmonary edema after fluid overload. In the western country, 3 population types of ACE genotypes exist (DD, ID, II). It is unknown whether the ACE genotype influences the response to fluid overload in ACE-inhibitor treated chronic heart failure patients.
Patients with chronic heart failure in stable clinical condition treated with ACE-inhibitors, but not aspirin, will be evaluated by means of maximal cardiopulmonary exercise test and lung function including lung diffusion measurements. These tests will be done before and after rapid 500 ml isotonic saline infusion. Patients will be grouped according to their ACE genotype.
Interventional
Not Provided
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Heart Failure, Congestive
Drug: isotonic saline infusion
Experimental: CMPD patients
Patients with CMPD with evaluation of ACE I/D polymorphism
Intervention: Drug: isotonic saline infusion

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • New York Heart Association (NYHA) class I and II heart failure
  • Chronic ACE-inhibitor treatment

Exclusion Criteria:

  • Aspirin treatment in the previous 2 months
Both
20 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT00361127
CCM S65/206
Not Provided
Not Provided
Not Provided
Piergiuseppe Agostoni, Centro Cardiologico Monzino
Piergiuseppe Agostoni
Not Provided
Principal Investigator: Piergiuseppe Agostoni, MD.PhD Centro Cardiologico Monzino
Centro Cardiologico Monzino
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP